{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:30:52Z","timestamp":1782862252701,"version":"3.54.5"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.4158\/ep13075.or","type":"journal-article","created":{"date-parts":[[2013,9,6]],"date-time":"2013-09-06T22:40:01Z","timestamp":1378507201000},"page":"120-128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Diabetes Duration and the Efficacy and Safety of Insulin Glargine Versus Comparator Treatment in Patients with Type 2 Diabetes Mellitus"],"prefix":"10.1016","volume":"20","author":[{"given":"Satish K.","family":"Garg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Aurand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Rimler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George E.","family":"Dailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4158\/EP13075.OR_bb0005","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","article-title":"Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49)","volume":"281","author":"Turner","year":"1999","journal-title":"JAMA."},{"key":"10.4158\/EP13075.OR_bb0010","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ."},{"key":"10.4158\/EP13075.OR_bb0015","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med."},{"key":"10.4158\/EP13075.OR_bb0020","doi-asserted-by":"crossref","first-page":"330","DOI":"10.2337\/diacare.25.2.330","article-title":"Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57)","volume":"25","author":"Wright","year":"2002","journal-title":"Diabetes Care."},{"key":"10.4158\/EP13075.OR_bb0025","first-page":"455","article-title":"Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study","volume":"57","author":"Calvert","year":"2007","journal-title":"Br J Gen Pract."},{"key":"10.4158\/EP13075.OR_bb0030","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11606-007-0139-y","article-title":"Delay of insulin addition to oral combination therapy despite inadequate glycemic control: delay of insulin therapy","volume":"22","author":"Nichols","year":"2007","journal-title":"J Gen Intern Med."},{"issue":"Suppl 2","key":"10.4158\/EP13075.OR_bb0035","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1463-1326.2008.00846.x","article-title":"Options for the intensification of insulin therapy when basal insulin is not enough in type 2 diabetes mellitus","volume":"10","author":"Raccah","year":"2008","journal-title":"Diabetes Obes Metab."},{"key":"10.4158\/EP13075.OR_bb0040","first-page":"2","article-title":"The natural history of type 2 diabetes: practical points to consider in developing prevention and treatment strategies","volume":"18","author":"Ramlo-Halsted","year":"2000","journal-title":"Clinical Diabetes."},{"key":"10.4158\/EP13075.OR_bb0045","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/qjmed\/hcp121","article-title":"Early onset type 2 diabetes mellitus: a harbinger for complications in later years--clinical observation from a secondary care cohort","volume":"102","author":"Song","year":"2009","journal-title":"QJM."},{"key":"10.4158\/EP13075.OR_bb0050","doi-asserted-by":"crossref","first-page":"704","DOI":"10.2337\/diacare.27.3.704","article-title":"The significant effect of diabetes duration on coronary heart disease mortality: the Framingham Heart Study","volume":"27","author":"Fox","year":"2004","journal-title":"Diabetes Care."},{"key":"10.4158\/EP13075.OR_bb0055","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1001\/archinternmed.2011.2","article-title":"Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors","volume":"171","author":"Wannamethee","year":"2011","journal-title":"Arch Intern Med."},{"key":"10.4158\/EP13075.OR_bb0060","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1464-5491.2006.01881.x","volume":"23","author":"Gerstein","year":"2006","journal-title":"Diabet Med."},{"key":"10.4158\/EP13075.OR_bb0065","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","article-title":"The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients","volume":"26","author":"Riddle","year":"2003","journal-title":"Diabetes Care."},{"key":"10.4158\/EP13075.OR_bb0070","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2337\/diacare.29.03.06.dc05-0695","article-title":"Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients","volume":"29","author":"Rosenstock","year":"2006","journal-title":"Diabetes Care."},{"key":"10.4158\/EP13075.OR_bb0075","doi-asserted-by":"crossref","first-page":"588","DOI":"10.4158\/EP09281.OR","article-title":"Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus","volume":"16","author":"Meneghini","year":"2010","journal-title":"Endocr Pract."},{"key":"10.4158\/EP13075.OR_bb0080","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2337\/diacare.28.2.254","article-title":"Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes","volume":"28","author":"Janka","year":"2005","journal-title":"Diabetes Care."},{"key":"10.4158\/EP13075.OR_bb0085","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/S0140-6736(08)60485-7","article-title":"Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial","volume":"371","author":"Bretzel","year":"2008","journal-title":"Lancet."},{"key":"10.4158\/EP13075.OR_bb0090","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1463-1326.2008.00980.x","article-title":"Insulin glargine provides greater improvements in glycaemic control vs intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels; the TULIP study","volume":"11","author":"Blickl\u00e9","year":"2009","journal-title":"Diabetes Obes Metab."},{"key":"10.4158\/EP13075.OR_bb0095","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s00125-005-0132-0","article-title":"Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study","volume":"49","author":"Yki-J\u00e4rvinen","year":"2006","journal-title":"Diabetologia."},{"key":"10.4158\/EP13075.OR_bb0100","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4065\/mcp.2009.0265","article-title":"Association between albuminuria and duration of diabetes and myocardial dysfunction and peripheral arterial disease among patients with stable coronary artery disease in the BARI 2D study","volume":"85","author":"Escobedo","year":"2010","journal-title":"Mayo Clin Proc."},{"key":"10.4158\/EP13075.OR_bb0105","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1055\/s-2008-1042404","article-title":"Influence of the duration of type 2 diabetes on early functional and morphological markers of atherosclerosis compared to the impact of coexisting classic cardiovascular risk factors","volume":"116","author":"Meyer","year":"2008","journal-title":"Exp Clin Endocrinol Diabetes."},{"key":"10.4158\/EP13075.OR_bb0110","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.2337\/dc07-0282","article-title":"Diabetic nephropathy in 27,805 children, adolescents, and adults with type 1 diabetes: effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset, and sex","volume":"30","author":"Raile","year":"2007","journal-title":"Diabetes Care."},{"key":"10.4158\/EP13075.OR_bb0115","first-page":"S262","article-title":"Duration of diabetes and hypoglycaemia rates in type 2 diabetes patients treated with insulin glargine vs NPH insulin","volume":"54","author":"Dailey","year":"2011","journal-title":"Diabetologia."},{"key":"10.4158\/EP13075.OR_bb0120","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/dom.12131","article-title":"Impact of diabetes duration on hypoglycaemia in patients with type 2 diabetes treated with insulin glargine or NPH insulin","volume":"15","author":"Dailey","year":"2013","journal-title":"Diabetes Obes Metab."}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20437383?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20437383?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/4772252712853811.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:56:24Z","timestamp":1761515784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20437383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S1530891X20437383"],"URL":"https:\/\/doi.org\/10.4158\/ep13075.or","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diabetes Duration and the Efficacy and Safety of Insulin Glargine Versus Comparator Treatment in Patients with Type 2 Diabetes Mellitus","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP13075.OR","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}